Cardium Therapeutics Announces Addition of Vice President
News Nov 24, 2005
Cardium Therapeutics Inc., a wholly-owned subsidiary of Aries Ventures Inc., has announced the addition of Jennifer A. Spinella as Vice President - Regulatory Affairs.
Christopher J. Reinhard, Chairman and Chief Executive Officer of Cardium Therapeutics said, "We are pleased to welcome Jennifer to Cardium Therapeutics. Jennifer's significant experience in pharmaceutical product development will assist us with the regulatory approval process relating to the commercial development of our lead product, Generx, a DNA-based angiogenic therapeutic."
Ms. Spinella was formerly Director of Regulatory Affairs at Biogen Idec Inc. and was responsible for the regulatory strategy and recent supplemental Biologics License Application (sBLA) for Rituxan® in Rheumatoid Arthritis.
Before joining Biogen Idec in 2003, she was Director of Regulatory Affairs at Idun Pharmaceuticals Inc. and held various regulatory positions at Elan Pharmaceuticals Inc., Chugai Biopharmaceuticals Inc., Dura Pharmaceuticals Inc. and Gensia Pharmaceuticals Inc.
Ms. Spinella earned her B.S. in Medical Technology from the University of Nebraska College of Medicine, Omaha, Nebraska.
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
SCRaMbLE Speeds Up Yeast EvolutionNews
Scientists have created a new way of speeding up the genome evolution of baker’s yeast Saccharomyces cerevisiae. This is to develop a synthetic yeast strain that can be transformed on demand, making it industrial applications such as the mass production of advanced medicines to treat illnesses such as malaria and tuberculosis (TB).READ MORE
Artificial Cellular Compartments BuiltNews
How to install new capabilities in cells without interfering with their metabolic processes? A team from the Technical University of Munich (TUM) and the Helmholtz Zentrum München have altered mammalian cells in such a way that they formed artificial compartments in which sequestered reactions could take place, allowing the detection of cells deep in the tissue and also their manipulation with magnetic fields.READ MORE